Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 4/2023

Open Access 07-11-2023 | Kidney Cancer | short review

Renal cell carcinoma

Author: Jasmin Spiegelberg

Published in: memo - Magazine of European Medical Oncology | Issue 4/2023

Login to get access

Summary

Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.
Literature
1.
Motzer RJ, Porta C, Eto M, et al. Final prespecified overall survival analysis of CLEAR: 4‑year follow-up of lenvatinib plus pembrolizumab vs sunitinib in patients with advanced renal cell carcinoma. 2023 ASCO Annual Meeting. Abstract 4502. 2023.
2.
Motzer R, Alekseev B, Rha SY, et al. CLEAR trial investigators: lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–300.CrossRefPubMed
3.
Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–41.CrossRefPubMed
4.
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27.CrossRefPubMed
5.
Powles T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomized, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–73.CrossRefPubMed
6.
Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicenter, randomized, open-labl, phase 3 trial. Lancet. 2023; https://​doi.​org/​10.​1016/​S0140-6736(23)00922-4.CrossRefPubMed
7.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ, COSMIC-313 Investigators. Cabozantinib plus nivolumab and Ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388(19):1767–78. https://​doi.​org/​10.​1056/​NEJMoa2212851.CrossRefPubMedPubMedCentral
Metadata
Title
Renal cell carcinoma
Author
Jasmin Spiegelberg
Publication date
07-11-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00918-w

Other articles of this Issue 4/2023

memo - Magazine of European Medical Oncology 4/2023 Go to the issue

short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

editorial

HER2 in focus—gastric cancer

short review

Focal therapy in intermediate- and high-risk prostate cancer

short review

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

short review

Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients

short review

ASCO 2023: new treatment options in CNS tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits